Gastroenterology & Metabolic Diseases, Cisanello Pisa University Hospital, Pisa, Italy.
Department of Medical & Surgical Sciences, Bologna University, Bologna, Italy.
Radiology Institute, Cisanello Pisa University Hospital, Pisa, Italy.
Gastroenterology, Brotzu Hospital, Cagliari, Italy.
Internal Medicine, Messina University, Messina, Italy.
Gastroenterology, Modena University, Modena, Italy.
Gastroenterology, Palermo University, DIBIMIS, Palermo, Italy.
General Surgery, Cisanello Pisa University Hospital, Pisa, Italy.
Gastroenterology, Cisanello Pisa University Hospital, Pisa, Italy.
This multicenter field-practice study evaluates outcomes of long-term sorafenib in hepatocellular carcinoma (HCC) patients.
Consecutive HCC patients on sorafenib were enrolled. We evaluated those receiving sorafenib for ≥12 months.
Out of 800 patients on sorafenib, 81 (10%) received long-term treatment. Median duration of treatment was 22.7 months (range: 12.3-92.6). Only 21 (26%) reported grade 3/4 adverse events. Complete response was reported in 11 patients (14%). Median overall survival was 34.8 months (95% CI: 29.9-44.3). Only baseline Child-Pugh class was associated with survival.
Sorafenib could result in long-term control of HCC in a relevant proportion of patients. Given the availability of regorafenib in the second-line setting, an earlier introduction of systemic therapy may be considered according to clinical indications.